Related Experiment Video
Updated: Feb 12, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma
Yohei Takeda1, Masahiro Azuma1, Kenji Funami1
1Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Abstract:
Mycoplasma fermentans-derived diacylated lipoprotein M161Ag (MALP404) is recognized by human/mouse toll-like receptor (TLR) 2/TLR6. Short proteolytic products including macrophage-activating lipopeptide 2 (MALP2) have been utilized as antitumor immune-enhancing adjuvants. We have chemically synthesized a short form of MALP2 named MALP2s (S-[2,3-bis(palmitoyloxy)propyl]-CGNNDE). MALP2 and MALP2s provoke natural killer (NK) cell activation in vitro but only poorly induce tumor regression using in vivo mouse models loading NK-sensitive tumors. Here, we identified the functional mechanism of MALP2s on dendritic cell (DC)-priming and cytotoxic T lymphocyte (CTL)-dependent tumor eradication using CTL-sensitive tumor-implant models EG7 and B16-OVA. Programmed death ligand-1 (PD-L1) blockade therapy in combination with MALP2s + ovalbumin (OVA) showed a significant additive effect on tumor growth suppression. MALP2s increased co-stimulators CD80/86 and CD40, which were totally MyD88-dependent, with no participation of toll-IL-1R homology domain-containing adaptor molecule-1 or type I interferon signaling in DC priming. MALP2s + OVA consequently augmented proliferation of OVA-specific CTLs in the spleen and at tumor sites. Chemokines and cytolytic factors were upregulated in the tumor. Strikingly, longer duration and reinvigoration of CTLs in spleen and tumors were accomplished by the addition of MALP2s + OVA to α-PD-L1 antibody (Ab) therapy compared to α-PD-L1 Ab monotherapy. Then, tumors regressed better in the MALP2s/OVA combination than in the α-PD-L1 Ab monotherapy. Hence, MALP2s/tumor-associated antigens combined with α-PD-L1 Ab is a good therapeutic strategy in some mouse models. Unfortunately, numerous patients are still resistant to PD-1/PD-L1 blockade, and good DC-priming adjuvants are desired. Cytokine toxicity by MALP2s remains to be settled, which should be improved by chemical modification in future studies.
Insights
A synthetic lipopeptide, MALP2s, enhances dendritic cell priming and cytotoxic T lymphocyte responses, improving tumor regression when combined with PD-L1 blockade therapy.
Area of Science:
- Immunology
- Cancer Biology
- Drug Discovery
Background:
- Macrophage-activating lipopeptide 2 (MALP2) and its derivatives are known for immune-enhancing properties.
- Previous studies utilized MALP2 as an antitumor adjuvant, but with limited efficacy in vivo.
- Dendritic cell (DC) priming and cytotoxic T lymphocyte (CTL) activation are crucial for effective anti-tumor immunity.
Purpose of the Study:
- To elucidate the mechanism of action of a synthetic MALP2 derivative, MALP2s, in dendritic cell priming and CTL-mediated tumor eradication.
- To evaluate the efficacy of MALP2s in combination with programmed death ligand-1 (PD-L1) blockade therapy for tumor regression.
- To identify key signaling pathways involved in MALP2s-induced DC activation.
Main Methods:
- Chemical synthesis of MALP2s.
- In vitro assessment of NK cell activation.
- In vivo studies using CTL-sensitive tumor models (EG7 and B16-OVA).
- Combination therapy with MALP2s, ovalbumin (OVA), and anti-PD-L1 antibody.
- Flow cytometry to analyze DC co-stimulatory molecules (CD80/86, CD40) and T cell populations.
- Assessment of chemokine and cytolytic factor expression in tumors.
- MyD88-dependent signaling pathway analysis.
Main Results:
- MALP2s effectively primes dendritic cells in a MyD88-dependent manner, independent of Toll-IL-1R homology domain-containing adaptor molecule-1 or type I interferon signaling.
- Combination therapy of MALP2s + OVA with anti-PD-L1 antibody demonstrated significant additive effects on tumor growth suppression compared to monotherapy.
- MALP2s + OVA augmented the proliferation and function of OVA-specific CTLs in both spleen and tumor sites, leading to increased chemokine and cytolytic factor production.
- Sustained CTL activity and enhanced tumor regression were observed with the combination therapy, outperforming anti-PD-L1 antibody monotherapy.
Conclusions:
- MALP2s, when combined with tumor-associated antigens and PD-L1 blockade, represents a promising therapeutic strategy for enhancing anti-tumor immunity in specific mouse models.
- The study highlights the potential of MALP2s as a DC-priming adjuvant to overcome resistance to PD-1/PD-L1 blockade.
- Further research is needed to address potential cytokine toxicity and optimize MALP2s through chemical modification for clinical application.
More Related Videos
08:11Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
Published on: September 1, 2015
09:31Inducible, Cell Type-Specific Expression in Arabidopsis thaliana Through LhGR-Mediated Trans-Activation
Published on: April 19, 2019
Related Concept Videos
Neurons: The Cell Body and the Dendrites
Induced Pluripotent Stem Cells
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test: